Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

33
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

31
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
31
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

32
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
32

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia.

Atherosclerosis plus·2026
Same author

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Journal of atherosclerosis and thrombosis·2026
Same author

Distribution of Lipoprotein(a) Levels Among Children with Elevated Low-Density Lipoprotein Cholesterol Identified Through Universal Pediatric Lipid Screening.

Journal of atherosclerosis and thrombosis·2026
Same author

Sex Differences in the Diagnosis and Treatment of Japanese Patients With Familial Hypercholesterolemia: A Retrospective Cohort Study.

Journal of lipid and atherosclerosis·2026
Same author

Current and Future Perspectives of LDL-C Lowering Therapies 2026.

Journal of atherosclerosis and thrombosis·2026
Same author

Severe HDL-C Deficiency Caused by Acquired LCAT Deficiency: A Case Report with Lipidomic Profiling and Anti-LCAT Autoantibody Detection.

Internal medicine (Tokyo, Japan)·2026

相关实验视频

Updated: Sep 9, 2025

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans
04:40

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans

Published on: August 28, 2018

15.3K

痛风,尿酸和冠状动脉疾病

Takuya Nakahashi1, Hayato Tada2, Kenji Sakata2

  • 1Division of Cardiology, Department of Internal Medicine, Takaoka City Hospital.

Journal of atherosclerosis and thrombosis
|August 31, 2025
PubMed
概括

高血清尿酸 (高尿血) 与心血管疾病和死亡率有关. 识别受益于尿酸降低的患者对于控制残留心血管风险至关重要.

科学领域:

  • 心脏病学
  • 生物化学
  • 关节病学

背景情况:

  • 血清尿酸高于7.0 mg/dL的高尿血是痛风的前体.
  • 它与高血压,糖尿病,脱脂症和死亡率的增加有关.
  • 升高的UA与动脉样硬化标志物和内皮功能障碍相关,这表明病原性与心血管事件的联系.

研究的目的:

  • 审查目前对冠状动脉疾病 (CAD) 的理解.
  • 讨论未来治疗多尿血症作为CAD患者残留风险因素的前景.

主要方法:

  • 关于高尿血和心血管疾病的现有证据的文献综述.
  • 分析UA升高与心血管不良事件之间的病原性联系.
  • 对痛风,酸盐 (MSU) 水晶沉积和心血管影响的检查.

主要成果:

  • 高尿血与心血管疾病 (CVD) 的增加率和死亡率有关.
  • 在冠状动脉中发生MSU晶体沉积,而不仅仅是关节.
  • 目前的尿酸降低疗法在降低高尿血症的心血管事件方面缺乏有效性.

结论:

  • 在患有CAD的患者中,高尿血症具有显著的残留风险.
关键词:
冠状动脉疾病双能计算断层扫描甲状腺炎血尿过高单酸盐晶体穿皮冠状动脉干预尿酸的使用

更多相关视频

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.7K
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

2.1K

相关实验视频

Last Updated: Sep 9, 2025

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans
04:40

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans

Published on: August 28, 2018

15.3K
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.7K
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

2.1K
  • 确定受益于UA减少的特定患者子组至关重要.
  • 需要进行进一步的研究,以建立在CAD中高尿血的有效治疗策略.